🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Nanox AI software for liver health gets FDA nod

EditorEmilio Ghigini
Published 02/13/2024, 08:20 AM
© Reuters.
NNOX
-

PETACH TIKVA, Israel - Nanox, known as Nano-X Imaging LTD (NASDAQ: NNOX), an innovative medical imaging technology company, announced today that its subsidiary, Nanox AI Ltd., has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its artificial intelligence (AI) software, HealthFLD. The AI software is designed to provide automated analysis of liver attenuation from CT scans and is intended to aid clinicians in detecting fatty liver, a condition associated with metabolic dysfunction-associated steatotic liver disease (MASLD).

HealthFLD can analyze both contrast and non-contrast chest and abdomen CT scans in patients aged 18 to 75. This clearance marks the third product in Nanox AI's suite of population health solutions to be commercially available. The software aims to support early detection of MASLD, a disease linked to obesity and cardiovascular disease, which affects an estimated 24% of U.S. adults. Early diagnosis is crucial, as MASLD is often asymptomatic until it progresses to more severe stages.

The FDA's decision is based on a study published in the American Journal of Roentgenology, which demonstrated HealthFLD's high performance in detecting at least moderate hepatic steatosis with a sensitivity of 77.8% and specificity of 93.2%. The clearance adds to Nanox's portfolio, which includes FDA-cleared solutions for coronary artery disease and musculoskeletal disease assessment.

Erez Meltzer, CEO of Nanox, expressed pride in the company's growing suite of AI-powered health solutions and noted the potential benefits of HealthFLD for the biopharmaceutical industry, particularly in streamlining candidate identification for clinical trials of liver disease therapies, including those for MASH.

Nanox AI, as a deep-learning medical imaging analytics subsidiary of Nanox, focuses on providing clinicians with actionable insights from routine medical imaging. The company's broader vision includes making diagnostic medicine more accessible and affordable globally through its ecosystem, which encompasses the Nanox.ARC system, Nanox.AI, Nanox.CLOUD infrastructure, and a decentralized marketplace for radiology and cardiology experts.

This news is based on a press release statement from Nanox and provides a factual report on the FDA clearance of HealthFLD, a new AI software for liver health analysis.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.